Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 10/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049782 | 0.88 | HSD17B10 (0.46) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5044973 | 0.84 | KIF18A (0.50) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5048443 | 0.84 | MAPK1 (0.50) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5048363 | 0.84 | CA2 (0.54) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5048797 | 0.84 | KIF18A (0.49) | MAPK1KDM4EHTTKMT2AKIF18A | |
| SCHEMBL5041969 | 0.81 | MAPK1 (0.49) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5045480 | 0.77 | KIF18A (0.51) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5032579 | 0.76 | HPGD (0.39) | MAPK1KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL5041107 | 0.76 | KIF18A (0.49) | MAPK1KDM4EHTTKMT2AKIF18A | |
| SCHEMBL5041069 | 0.75 | MAPK1 (0.49) | MAPK1KDM4EHTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | claimed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | claimed |
| US-7378417-B2 | Pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | MAPK1 1732/4885KDM4E 3638/4885HTT 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.